. Antibody discovery timelines. Publications and patent applications describing the "in silico designed" antibodies are shown in red font. , and survival (C) in A129 mice. A total of 2 mg/kg (~60 µg) ZAb_FLEP reduces viremia and provides complete protection against weight loss and survival. Remarkably, there were no observable differences in viremia or accelerated death even when significantly lower doses (0.2 mg/kg ~ 6 µg) of ZAb_FLEP were administered. N = 5 for each condition, experiment performed twice, error bars indicate SD of the data, *p < 0.05, ***p < 0.001.
